Aberdeen Group
GBT

Aberdeen Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Aberdeen Group’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-23,684
Closed -$735K – 799
2017
Q3 		$735K Buy
+23,684
New +$666K ﹤0.01% 741

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Aberdeen Group's GBT Position: Q4 2017 in Review

Aberdeen Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2017, closing a stake of 23,684 shares — an estimated $735K sold.

Aberdeen Group first reported a position in GBT in Q3 2017 and held it in 1 quarter. The position peaked at $735K in Q3 2017. 157 funds tracked by Wall St. Rank hold GBT as of Q4 2017.

  • Aberdeen Group reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Aberdeen Group sold 23,684 Global Blood Therapeutics, Inc. shares in Q4 2017, an estimated $735K.
  • Aberdeen Group first reported a position in Global Blood Therapeutics, Inc. in Q3 2017 and held it in 1 quarter.
  • Aberdeen Group's Global Blood Therapeutics, Inc. position peaked at $735K in Q3 2017.
  • 157 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2017.

Based on Aberdeen Group's 13F filing for Q4 2017, filed 12 Feb 2018.